Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H; SWITCH-SEMA 1 study group. Takahashi Y, et al. Among authors: nomoto h. Diabetes Obes Metab. 2023 Jun;25(6):1503-1511. doi: 10.1111/dom.14998. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36722623 Clinical Trial.
Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion assessed using continuous glucose monitoring: A prospective observational study.
Miya A, Nakamura A, Suzuki Y, Nomoto H, Kameda H, Cho KY, Ito YM, Nagai S, Miyoshi H, Atsumi T. Miya A, et al. Among authors: nomoto h. Diabetes Obes Metab. 2023 Jul;25(7):1883-1889. doi: 10.1111/dom.15049. Epub 2023 Mar 31. Diabetes Obes Metab. 2023. PMID: 36906821
A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study).
Takahashi A, Nomoto H, Onishi K, Manda S, Miya A, Kameda H, Nakamura A, Atsumi T. Takahashi A, et al. Among authors: nomoto h. Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15639. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38699794 No abstract available.
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).
Furusawa S, Nomoto H, Oba-Yamamoto C, Takeuchi J, Ito M, Kurihara H, Aoki S, Miya A, Kameda H, Nakamura A, Atsumi T. Furusawa S, et al. Among authors: nomoto h. Endocr J. 2024 Apr 25. doi: 10.1507/endocrj.EJ23-0648. Online ahead of print. Endocr J. 2024. PMID: 38658349 Free article.
374 results